Axsome Therapeutics

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Axsome Therapeutics is dedicated to discovering and developing novel therapies to improve and extend the lives of people with CNS disorders.

Axsome Therapeutics is committed to making a meaningful difference in the lives of people suffering from CNS disorders by developing therapies that have the potential to significantly improve patient outcomes.

Axsome Therapeutics has received several awards, including being named to the 2019 FierceBiotech list of “Fierce 15” companies, recognizing Axsome as one of the most promising privately-held biotechnology companies in the industry.